EDWARD GENTON, M.D., F.A.C.P.; LIBERTO PECHET, M.D.
This content is PDF only. Please click on the PDF icon to access.
The feasibility of dissolving intravascular fibrin deposits by enzymatic means (thrombolysis) appears established, and the prospect of clinical use of this method has stimulated efforts to develop suitable agents. An ideal thrombolytic agent would have various properties, including effectiveness, safety, nonantigenicity, availability, and simplicity of use. Necessarily, such agents would regularly produce thrombolysis in a variety of thromboembolic states, resulting in restoration of circulation to involved areas, preservation of tissue viability, and reversal of the hemodynamic consequences of vascular thrombosis. A predictable degree of activity would be producible without creating adverse effects such as hypotension, febrile
reactions, or coagulation alterations.
GENTON E, PECHET L. Thrombolytic Agents: A Perspective. Ann Intern Med. ;69:625–628. doi: 10.7326/0003-4819-69-3-625
Download citation file:
Published: Ann Intern Med. 1968;69(3):625-628.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use